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Abstract 
Protein phosphorylation is an important post-translational modification that is an integral 
part of cellular function. The O-phosphorylated amino acid residues such as phosphoserine 
(pSer), phosphothreonine (pThr) and phosphotyrosine (pTyr), have dominated the literature 
whilst the acid labile N-linked phosphorylated amino acids, such as phosphohistidine (pHis), 
have largely been historically overlooked due to the acidic conditions routinely used in 
amino acid detection and analysis. This review highlights some misinterpretations that have 
arisen in the existing literature, pinpoints outstanding questions and potential future 
directions to clarify the role of pHis in mammalian signalling systems. Particular emphasis is 
placed on pHis isomerisation and the hybrid functionality for both pHis and pTyr of the 
ƉƌŽƉŽƐĞĚʏ-pHis analogue bearing the triazole residue. 
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Introduction 
Protein phosphorylation is one of the most commonly studied post-translational 
modifications. In general, the phosphorylation of any amino acid residue results in a change 
in charge and thus in the protein surface potential. For example, since phosphoryl groups 
exist mostly as a dianion under physiological conditions,1 phosphorylation of the amino 
acids serine (Ser), threonine (Thr), and tyrosine (Tyr), results in a change from neutral to 
negative (-2). Hence, it should be of no surprise that phosphorylation affects protein 
conformation, protein-protein interactions, biochemical pathways and its dysregulation is 
connected to many disease states.2  
There are nine known phosphorylated amino acid residues Ser, Thr, Tyr, histidine (His), 
lysine (Lys), arginine (Arg), aspartic acid (Asp), glutamic acid (Glu), and cysteine (Cys).2 The 
hydroxy O-linked phospho-residues, pSer, pThr, and pTyr have been extensively studied, 
most probably due to their relative stability in acidic conditions routinely used for analysis. 
Hence the relatively acid labile N-linked phosphoramidate, carboxy O-linked acyl phosphate 
and S-linked phosphorothiolate amino acid residues (His, Lys, Arg; Asp, Glu; Cys respectively) 
have been largely overlooked and less frequently reported. Among the phosphoramidates, 
phosphohistidine (pHis) is very interesting because of its unique chemical properties: firstly, 
unlike other phosphorylated residues there are two isomers of pHis; ʏ- and ʋ-pHis, both of 
which are found in nature (Figure 1).3, 4 The ʏ- and ʋ-pHis are chemically different from each 
other in both structure, reactivity and stability under certain conditions (vide infra). 
Whether the differences in reactivity and stability are mirrored in proteins is not clear at 
present. Secondly, pHis serves as a high energy intermediate in the transfer of the 
phosphoryl group to other amino acid residues which is a characteristic not seen with other 
phosphorylated amino acid residues. Therefore, not only does pHis change the surface 
potential of proteins it also possesses transient transferable chemical information that can 
be potentially tuned depending on the isomer and environment.  
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Figure 1 The two isomers of pHis ?ʏ (tele)- ĂŶĚʋ(pros)-pHis residues found in nature existing as dianions under 
physiological conditions. dŚĞʏ isomer is also known ɸ ? ?-pHis, and ƚŚĞʋŝƐŽŵĞƌas ɷ ? ?-pHis. 
 
His phosphorylation has been found in a number of organisms including bacteria,5 fungi,6 
and plants7 and its major role is in cell signalling either via two component or 
multicomponent phosphorelay systems. Cell signalling via a two component phosphorelay 
has also been found in yeast,6 but such processes have not yet been observed in higher 
eukaryotes (for example mammals, birds and fish).8 The general role of pHis in prokaryotic 
and lower eukaryotic cells is shown in Figure 2.  
 
Figure 2 A simplified adopted schematic9 showing the general role of pHis known thus far10  
 
Two isoforms of nucleoside diphosphate kinase (NDPK): Nme1/NDPK-A11-15 and 
Nme2/NDPK-B16-21 have been characterised as mammalian His kinases. Other mammalian 
His kinases exist. Evidence for Histone H4 His kinases (HHKs) activity has been found in 
regenerating rat liver,22-25 foetal rat and human liver,25 human hepatocarcinoma tissue,25 
ƉĂŶĐƌĞĂƚŝĐɴ ĐĞůůƐ,26, 27 thymus28 and Walker-256 carcinosarcomas,22, 29 but have not been 
fully characterised or purified. Interestingly, HHKs from regenerating rat liver23 and Walker-
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256-carcinosarcomas29 each phosphorylated histone H4 leading to a ʏ-pHis residue. In a 
later study, 31P NMR suggested the presence of ʏ-pHis on His18 of phosphorylated histone 
H4 when Walker-256-carcinosarcomas were used as the kinase source.30 However, 31P NMR 
studies suggested the presence of ʋ-pHis in phosphorylated histone H4 when using 
regenerating rat liver as the kinase source.30 In this particular case it is not clear which 
isomer of pHis is formed and on which His residue. Mammalian pHis phosphatases which 
have been characterised include: protein pHis phosphatase 1 (PHPT1);19, 31-37 Lys/His 
phosphatase (LHPPase);38, 39 serine threonine protein phosphatases (PP1/2A/2C); 40, 41 T cell 
Ubiquitin Ligand-2 (TULA-2);42, 43 and the recently reported phosphoglycerate mutase-5 
(PGAM5).44 Additionally, pHis phosphatase activity has been reported in rat tissue extracts 
but these have not been fully characterised.45-48 
Not only is His phosphorylation predicted to be prevalent in eukaryotic proteins40 it has also 
been associated with important mammalian cellular processes. For example, pHis has been 
shown to be present in heteromeric G proteins (GNB1) which are involved in G protein 
signalling,17, 49, 50 KCa3.1 potassium channel which is involved in ion conductance,20, 51 ATP-
citrate lyase (ACLY) which is involved in cell metabolism,11 Histone H4 which is involved in 
chromatin biology,23, 24, 30 transient receptor potential-vanilloid-5 (TRPV5) which regulates 
urinary Ca2+ excretion,19 and phosphoglycerate mutase 1 (PGAM1) which is involved in 
glycolysis.52-55 Other mammalian pHis proteins include P-selectin, which plays an important 
role in the function of blood platelets,56 annexin A1 a multi-functional Ca2+ dependant 
phospholipid binding protein found in airway epithelia cells, 57 thymidylate synthase which 
catalyses N-methylenetetrahydrofolate assisted C(5)-methylation of dUMP required for DNA 
synthesis,58 glucose-6-phosphatase involved in glucose homeostasis,59, 60 nicotinamide 
phosphotransferase (NAMTP) involved in reforming nicotinamide adenine dinucleotide 
(NAD+) from nicotinamide61 and prostatic acid phosphatase which is found in high levels in 
prostate cancer cells.62, 63 However, the functions of many of these pHis proteins, and the 
specific pHis isomer involved, as well as corresponding kinases and phosphatases remain 
unknown. 
 
Chemistry of phosphohistidine 
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The chemistry of pHis amino acid was first studied by Hultquist et al.64, 65 and has been 
covered extensively in a review by Attwood.66 In summary, pHis residues contain a weak 
phosphoramidate bond with the phosphoryl group being most susceptible to hydrolysis 
when the imidazole nitrogen is protonated (Scheme 1).64, 65 Hence, the rate of hydrolysis of 
the pHis is dependent on pH. The respective pKa values of the imidazole nitrogen suggests 
hydrolysis can occur even under physiological conditions (pKa 7.3 for ʋ-pHis at 46 °C65 and 
pKa 6.4 for ʏ-pHis at 25 °C64). It is important to note that pHis pKa values have been found to 
vary depending on salts in solution. Gassner et al., found ʋ-and ʏ-pHis to have a pKas of 7.74 
and 6.88 respectively from the titration of the reaction mixture of His with potassium 
phosphoramidate adjusted to pH 7.2 at 25 °C.67  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1 Hydrolysis of the protonated ʏ- and ʋ- pHis imidazole nitrogen to His and phosphate. 
 
Hultquist studied the decomposition of ʏ-pHis over the pH range 2-5, by following the 
decrease in absorbance ŽĨʏ-pHis, and the decomposition of ʋ-pHis over the pH range 2-11 
by following the increase in absorbance of His, each at 46 °C.65 Both isomers decompose 
more rapidly at low pH and, at all pHs measured, ʋ-pHis was less stable than ʏ-pHis. Unlike 
ʏ-pHis, the rate constant for dephosphorylation of ʋ-pHis decreases smoothly between pH 
2-4, and remains approximately constant over the pH range 4-6; above pH 6 (~ pKa of 
imidazole nitrogen ŽĨ ʋ-pHis) to pH 9 the rate constant decrease slowly again before a 
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further decrease above pH 9 which is approximately the pKa of the amine (~9.6).64-66 
Nonetheless, the data clearly shows both ʋ-His (pH 9-11, 46 °C)65 and ʏ-pHis (pH 8-10, 80.5 
°C)64 are stable in solution for extended periods provided the right conditions are used. 
Hence, application of pHis standards in experiments such as ELISA, chromatography, and dot 
blots with protein conjugates, or any other test where the pHis standard is needed, should 
be possible.  
 
Within a small neutral peptide (Gly-pHis-Gly) Lecroisey et al. found the ʋ-pHis residue to be 
less stable than the ʏ-pHis residue in the same position, ĐŽŶƐŝƐƚĞŶƚǁŝƚŚ,ƵůƚƋƵŝƐƚ ?ƐĨŝŶĚŝŶŐs.3 
Whether the relative stability of ʋ- and ʏ-pHis residues in this case could be explained by 
pKa alone is questionable (due to the absence of the primary amine) because it is not known 
to what extent the peptide backbone affects pHis stability. Furthermore, a denatured pHis 
protein where tertiary interactions are absent may have a half-life that differs from that in 
the tertiary structure.3, 68 For example, the enzyme NDPK has a His residue within its active 
site, which interacts with a nearby Glu residue assisting in the isomer selective 
phosphorylation to form ʋ-pHis, but this interaction is absent in the denatured state.69, 70 
Hence, procedures where denaturants are used such as Western blots must take this into 
account. Another important factor to consider in any procedure involving pHis is the 
type/concentration of salts present in solution. For example, the calcium salt of ʋ-pHis was 
found to be very unstable relative to the sodium salt of ʋ-pHis.65 Thus, each protein 
phosphorylated on a His residue will likely have a unique half-life under a defined set of 
conditions and as such, meaningful half-life comparisons can only be made between pHis 
proteins using normalised conditions. 
An important question to be addressed is: does ʋ-pHis isomerise to ʏ-pHis or vice versa 
under any conditions because this will have implications for methods used to study pHis? A 
good place to start to address the question of isomerisation is from the work by Hultquist et 
al., who reported the synthesis, purification and subsequent experimental work on each 
pHis isomer.64, 65  
Reaction of His with potassium phosphoramidate in water gives both isomers of pHis as well 
as bis-pHis (Scheme 2). The pHis isomers were separated using anion exchange 
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chromatography as either lithium, potassium64 or sodium salts65 after desalting. By following 
the progress of the reaction by electrophoresis it was established that ʋ-pHis formed rapidly 
before gradually decreasing, accompanied by the formation of ʏ-pHis and bis-pHis. Similar, 
observations were made in 1H NMR studies by Gassner et al., where phosphorylation with 
potassium phosphoramidate (pH 7.2, 25°C) resulted in initial rapid formation of ʋ-pHis 
(maximum at ~ 10 mins), then bis-pHis (maximum at ~ 60 mins), both of which subsequently 
decomposed, accompanied by a gradual increase in ʏ-pHis.67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2 Synthesis of ʋ-pHis, ʏ-pHis and bis-pHis by reaction of His with potassium phosphoramidate in 
water. 
 
The observation of ʋ-pHis forming more rapidly is consistent with the major tautomer (ʏ 
protonated nitrogen) of His present in water (Scheme 2).71 Hultquisƚ ?ƐƉŚŽƐƉŚŽƌǇůƚƌĂŶƐĨĞƌ
experiments can be used as a plausible explanation for the accumulation of ʏ-pHis with the 
decrease in ʋ- and bis-pHis over time (Scheme 3). Phosphoryl transfer reactions (1)-(8) 
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suggest that the phosphoryl group of pHis can be donated to the imidazole nitrogen of His 
Žƌɲ-N-acetyl-His. Comparison of (1), and (5), with (7) and (8) suggests that ʋ-pHis has the 
more labile phosphorus nitrogen (P-N) bond compared to ʏ-pHis. Reactions (2) and (4) also 
show there is a preferential transfer of the ʋ-phosphoryl group of bis-pHis ƚŽ ĨŽƌŵ ƚŚĞ ʏ-
pHis. These observations are dependent upon the reaction conditions used (0.1 M Tris 
buffer, pH 8.5, at 4 °C)64 but provide a credible explanation as to how ʏ-pHis accumulates 
over time from the reaction of His and potassium phosphoramidate. 
 
Scheme 3. Phosphoryl transfer reactions of ʋ-pHis, ʏ-pHis and bis-pHis as donors and His and ɲ-N-acetyl-His as 
acceptors in 0.1 M Tris buffer, pH 8.5, at 4 °C.65 
 
Importantly, reactions (1), (5) and (7) show that one isomer of pHis can convert to the other 
isomer, but only via a bimolecular reaction with His. Though this can be viewed as 
isomerisation, it is in fact a bimolecular process and strictly not a unimolecular isomerisation 
as has been proposed to occur under certain conditions, both for pHis and pHis residues 
(Scheme 4).72-76 Indeed, Hultquist himself avoided the term isomerisation and defined 
reactions (1), (5), and (7) as conversion of one isomer to the other.65 It is unlikely 
unimolecular isomerisation is occurring under acidic conditions because the hydrolysis of 
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the calcium salt of ʋ-pHis (1 M HCl, 49 °C)65 and the lithium salt of ʏ-pHis (0.5 M HCl, 48.5 
°C)64 followed first order rate kinetics. 
 
 
 
 
 
 
Scheme 4 Inferred unimolecular isomerisation of ʋ-pHis to ʏ-pHis and vice versa that does not occur. 
 
Concerning the question of isomerisation of pHis residues in proteins, Lecroisey et al., found 
using 31P NMR only the ʋ-pHis residue both in chemically phosphorylated Dictyostelium 
NDPK (25 °C, 50 mM Tris-HCl, 10% D2O, pH 8.1) and in the denatured state after treatment 
with 9 M urea (vide supra).3 Similarly, Williams et al., observed only ʏ-pHis by 31P NMR in rat 
liver ACLY (25 mg/ml, 50 mM Tris-HCl, 14% D2O, pH 8.4) both for the functioning enzyme 
and when denatured with 1 % SDS and 1% ɴ-mercaptoethanol.77 Wagner et al., found that 
upon base hydrolysis (3 M KOH, 120 °C, 100 mins) of  ?ɶ-32P]ATP phosphorylated rat liver 
NDPK, only ʋ-pHis was detected in the hydrolysate by TLC analysis against the reference 
compound.11 In the same study only ʏ-pHis was detected by TLC from the base hydrolysate 
of (32P) phosphorylated rat adrenal ACLY.11 These results demonstrate that in these specific 
examples, isomerisation of the pHis residue does not occur. 
By contrast, in two early studies of phosphorylated human erythrocytic NDPK78 by Walinder 
et al., and of rat liver ACLY79 by Mardh et al., phospholysine (pLys) and both isomers of pHis 
were found in the base hydrolysate after chromatographic separation of the phospho amino 
acids. However, 31P NMR,3 X-ray crystallography  ?ŽŶůǇƚŚĞʋŝŵŝĚĂzole nitrogen is available 
for phosphorylation),69, 70 and base hydrolysate data,11 have shown that NDPK is 
autophosphorylated by ATP on a specific His residue to form the ʋ-pHis residue exclusively. 
Likewise ACLY has been found to be phosphorylated by NDPK or ATP to form ʏ-pHis only, 
both by 31P NMR and in the base hydrolysate.11 So why the discrepancy with the results 
from Walinder et al. and Mardh et al.? It may be that the phosphoryl group of one isomer of 
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pHis was transferred either directly to another His residue giving the other pHis isomer 
(Scheme 3, eq. 1 and eq. 7), or to a Lys residue (nitrogen lone pairs are known to accept the 
phosphoryl group from phosphoramidate containing compounds),80, 81 which then 
subsequently phosphorylated His under the particular experimental and analysis conditions 
used. 
Although, in this review we have focused the topic of pHis isomerisation mainly on the ACLY 
and NDPK, there are other examples of pHis containing proteins which have been 
characterised by 31P NMR, or X-ray crystallography and show no evidence of isomerisation. 
For examples see: Histone H4,30 Succinyl -CoA synthase,68 and phosphocarrier protein HPr.67  
 
Detection of phosphohistidine 
There are many ways to detect pHis and extensive reviews on the subject exist.72, 75, 82 
However, in the context of this review, some of the most important methods need to be 
discussed briefly. Detection of pHis residues using antibodies will be discussed in a later 
section. 31P NMR spectroscopy is a useful spectroscopic method to detect pHis residues but 
requires large amounts of purified sample. Nonetheless, it is one of the methods that allows 
pHis isomer distinction against pHis standard chemical shifts. In some cases, the local 
peptide sequence of the pHis residue is required to generate reference chemical shifts of ʋ- 
and ʏ-pHis residues within a sequence and this is not always known. For example, Lecroisey 
et al., found that the 31P NMR chemical shifts of phosphorylated NDPK did not match any 
ŬŶŽǁŶ ʏ-Ɖ,ŝƐ Žƌ ʋ-pHis 31P NMR chemical shifts.3 The chemical shifts of the pHis residue 
also differed by a large amount in the native (-2.72 ppm) and denatured state (-4.20 ppm) 
(vide supra for conditions).3 However, ʋ-His phosphorylated peptide (Glu-pHis-Gly, known 
phosphorylated sequence of NDPK) matched the denatured state chemical shift which was 
used as a reference.3 Another consideration that must be taken into account when 
characterising pHis by 31P NMR is pH because there are three states the phosphoryl group 
can exist in; as the phosphonic acid, monoanion, and dianion which will effect chemical 
shifts.67 Usually basic conditions (pH > 8) which stabilise pHis are used, where the 
phosphoryl groups exists as a dianion.1  
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Wagner et al., approach of detecting ĞŝƚŚĞƌʋ- or ʏ-pHis from the base hydrolysate of pHis 
proteins by TLC analysis against pHis standards seems encouraging due to the simplicity of 
the method.11 However, Wagner et al. used  ?ɶ-32P]ATP to phosphorylate the protein 
samples and the TLC was analysed by autoradiography. On the other hand detection of ʏ-
pHis in the base hydrolysate of enzymatically phosphorylated histone H4 using HPLC against 
pHis standards has been reported and could be used as an alternative.83 The method of base 
hydrolysis, though useful, cannot give any direct information about the site of His 
phosphorylation or the presence of multiple pHis residues in the protein. 
Mass spectrometry (MS) has been used in the detection of phosphorylated amino acid 
residues, including phosphorylated His residues.72 MS generally uses acidic eluents in 
chromatographic separation of enzymatically digested peptides prior to analysis, conditions 
which are not suitable for pHis containing proteins. However, changing the eluent to basic 
or neutral solution decreases the resolution and sensitivity but mildly acidic conditions 
(0.5% aqueous acetic acid) have proved successful so long as the contact time is kept to a 
minimum.84 Aqueous formic acid (0.1%) has also been used.85 
One of the challenges with MS analysis is how to eliminate false positives when analysing 
pHis data. For example, Gonzalez-Sanchez et al. found phosphorylation of peptide 
DAPAHDAKD with potassium phosphoramidate resulted in exclusive His phosphorylation 
which was confirmed by collision-induced dissociation-tandem MS.72 The same peptide 
analysed by nano-ultraperformance liquid chromatography nano-electrospray ionisation 
MS, eluted with 50 mM ammonium acetate and then loaded under acid conditions (pH 2) 
gave two distinct peaks. One peak was identified as the His phosphorylated peptide 
(DAPApHDAKD) and the other as the phosphorylated aspartate peptide (DAPAHpDAKD).72 
The latter experiment demonstrates false positives could be an issue in pHis proteomic MS 
analysis using certain techniques. Nevertheless, in a recent study Oslund et al. observed a 
characteristic TRIPLET fingerprint for the decomposition of the pHis residues (neutral losses 
of 98, 80 and 116 Da) in collision induced dissociation MS analysis of various pHis containing 
peptides, which could be used to differentiate pHis from other phosphorylated residues.85  
All the pHis detection methods described so far require an effective enrichment and 
purification strategy as well as a selective phosphorylation method. This can be quite tricky 
if the protein of interest requires a pHis kinase for phosphorylation because the pHis kinase 
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may be unknown or will also have to be isolated and phosphorylated. Lapek et al., has 
developed an MS method for the direct analysis of a whole cell lysate which helps preserve 
acid labile modifications by using a buffer mixture including ammonium bicarbonate 
between pH 2.5- 5 (adjusted with formic acid) in the chromatography prior to MS analysis.86 
Twenty pHis phosphopeptides were identified but the authors argue that the buffer system 
limits the analysis to peptide sequences possessing an intrinsic positive charge. Traditional 
methods avoid this by using more acidic conditions to positively charge the peptide but this 
is undesirable with acid labile phosphorylated residues.  
Despite MS being a powerful tool for the analysis of post-translational modifications it 
cannot give any direct information about the pHis isomer present which is an important 
requirement. Thus, the use of a variety of detection methods which complement each other 
is needed.  
 
Enrichment of phosphohistidine 
The most common ways to enrich a phosphoprotein use an immobilised metal affinity 
column (IMAC), an immobilised metal oxide columns (IMOC) or an immobilised phospho 
selective antibody (vide infra). The latter has been more successful due to it being generally 
more selective for a specific amino acid residue.87 Enrichment of pHis containing proteins 
using IMAC has had some success but has its limitations. Muimo et al. enriched His 
phosphorylated Annexin A1 with Fe3+ and Ca2+ affinity columns, but the method was found 
to be inefficient.57 Napper et al., used Cu2+ in what they describe as the selective enrichment 
of pHis-containing HPr protein from E.coli.88 However, this technique is limited to peptides. 
These two examples suggest IMAC can be used to enrich pHis samples but requires 
optimization to avoid the acidic conditions typically used to release the bound pHis proteins 
from the resin which destroys pHis residues and reduces efficiency.  
 
Phosphohistidine analogues and antibodies  
Antibodies have been used extensively in the detection and enrichment of other 
phosphorylated residues, namely pTyr, pSer and pThr.87 The development of pTyr 
antibodies in the ůĂƚĞ  ? ? ?Ɛ ůĞĚ ƚŽ Ă ďŽŽŵ ŝŶ ƚŚĞ research field and this arguably led 
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ultimately to the discovery of protein kinase inhibitor drug Gleevec, which is used to treat 
leukaemia and other malignancies.89-91  Among the detection methods which have been 
used to detect phosphorylated amino acid residues, such as MS, NMR spectroscopy, 
radiolabelling (32P), and dyes, antibodies hold the most potential. Antibodies allow for rapid 
non-invasive detection (can be used in vivo and in vitro), with high sensitivity (up to 
femtomolar detection92) and can be used in enrichment (perhaps most importantly because 
nearly all the detection methods discussed require a reliable enrichment process prior to 
analysis) from whole cell lysates.93 None of the other methods mentioned above has these 
three characteristics in combination and furthermore antibodies do not have many of the 
disadvantages associated with other techniques (vide supra) so long as they are selective for 
a particular antigen or target. 
 
There have not been any reports whereby pHis has been used successfully to generate 
selective antibodies, most likely due to its labile nature. Many authors have reported 
potential pHis analogues (Figure 3) and one of the first approaches was to substitute one of 
the oxygens of the phosphoryl group for a sulphur atom to give thiophosphorylhistidine 1 to 
give a more stable derivative of pHis.94 There are no reports of analogue 1 in the generation 
of pHis antibodies. An antibody was raised against the thiophosphorylhistidine derivative 2 
but the antibody so raised could not distinguish pHis from other phosphoamino acids. 95, 96 
Pirrung et al., reported the preparation of malonate 3 and fluoromalonate 4 derivatives of 
His as ʏ-pHis analogues.97 However, no biochemical studies using these analogues have been 
reported. Schenkels et al., reported the synthesis of protected phosphofurylalanine 5 whilst 
also proposing phosphopyrrole 7 as a potential ʏ-pHis analogue.98 Use of the free amino acid 
phosphofurylalanine 6 allowed the raising of antibodies, but these only detected the 
antigen, and not natural pHis.99 The phosphopyrrole 7 was later synthesised by Attwood et 
al.,66 but the polyclonal antibodies raised against this epitope detected only the analogue 
and not pHis. Following Schenkels ? proposal of phosphofurylalanine 6 as a potential pHis 
analogue, Lilley et al. synthesised phosphothiophene 8. Polyclonal antibodies generated 
against this epitope were found to be highly selective for pTyr but did not detect pHis. The 
results obtained with phosphopyrrole 7 and phosphothiophene 8 suggested that retaining 
the nitrogen with a lone pair of electrons relative to the phosphoryl group as present in pHis 
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was necessary. In addition, replacement of the labile phosphorus nitrogen bond (P-N) with a 
phosphorus carbon (P-C) is probably essential. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Some of the potential analogues of pHis. 
 
Eerland et al., designed and synthesised sulphonamide 9 as a sulphonamide based 
transition-state analogue of enzymatic pHis dephosphorylation (Figure 4).100 The analogue 
was successfully incorporated into peptides, but efforts to use these peptides as pHis 
phosphatase (PHT) inhibitors, or as baits to pull down pHis-binding proteins, were 
unfortunately unsuccessful.101 
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Figure 4 Sulphonamide based transition state enzymatic pHis dephosphorylation analogue of pHis. 
 
Kee et al., synthesised triazole analogues 10 and 12 as ʏ- and ʋ-pHis analogues respectively 
(Figure 5).102 Density functional theory (DFT) calculations on the residue of triazole analogue 
10 suggested a close structural match to ʏ-pHis but with an observable difference in 
electrostatic surface potential around the extra nitrogen and lone pair of electrons103 (see 
also Supplementary Figure S1102). Both analogues were incorporated into peptides via Boc 
solid phase peptide synthesis (SPPS) and peptide 11 was used to generate antibodies after 
being conjugated to protein KLH (Figure 5). The polyclonal antibodies were found to cross 
react with pHis substituted peptide 11 as assessed by dot blots but not in a peptide 
sequence independent manner (Rb.#3 antibodies showed significant cross reactivity with 
pTyr containing peptide, see Figure S4102). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Incorporation of proposed ʏ- ĂŶĚʋ-pHis analogues 10 and 12 in to peptides. 
 
Since this first report a number of groups have reported the synthesis of these analogues 
with different protecting groups to allow for incorporation of triazolylalanine 10 into 
peptides using Fmoc SPPS.104-106 In a 2012 paper McAllister et al., reported the synthesis of 
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Fmoc dibenzyl protected triazolylalanine 13 (Figure 6), which were incorporated into 
peptides via the Fmoc SPPS strategy.105 In a later paper, both triazolylalanine analogues 13 
and 14 were synthesised by Fuhs et al., and incorporated into degenerate peptides again 
using the Fmoc SPPS strategy (Figure 6 and Figure 8).74 
 
 
 
 
 
 
 
Figure 6 Fmoc SPPS compatible triazolylalanine 13 and 14 pHis analogues. 
 
Inspired by the earlier work on the generation of pTyr antibodies using the hapten107 alone 
Kee et al., used the triazolyl ethylamine 15 conjugated to KLH via a linker to give a much 
simpler epitope for use in immunisation (Figure 7).76 The affinity purified antibodies were 
used to detect pHis in various known peptides where phosphorylation sites vary widely, 
including histone H4, bacterial His kinase, KinB, and the E.Coli metabolic enzyme I (PtsI) and 
PpSA, illustrating its sequence independence.76 However, control experiments to assess the 
selectivity of the antibody against other phosphorylated amino acids/peptides showed 
significant cross-reactivity with pTyr as observed by ELISA and dot blots (see Supplementary 
Figure 3, 5 and 6).85 These results suggest the triazolyl residue 16 has a hybrid functionality 
for both pHis and pTyr in antibody generation, perhaps similar to the azobenzene reported 
in the 1980s.108 Despite the limitations, Kee et al., study has demonstrated that pHis 
analogues alone could be effective as epitopes. 
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Figure 7 Triazolyl ethylamine synthesised by Kee et al.100 
 
Fuhs et al., took both 13 and 14 and incorporated them in neutral peptides libraries (Figure 
7).74 Immunisation with peptides libraries including 16 and 17 conjugated to KLH generated 
polyclonal antibodies. The antibodies were tested by dotblots/immunoblots against peptide 
immunogens 16 and 17, pTyr peptides and two protein targets as standards, His 
phosphorylated NME1/NME2 and PGAM, which contain a ʋ-His or a ʏ-pHis residue 
respectively (Figure 9). Analysis by immunoblots showed the polyclonal antibodies raised 
against triazolyl peptides 17 recognised phosphorylated PGAM, while the polyclonal 
antibody raised against triazolyl peptides 16 recognised, in a complementary way, 
phosphorylated NME1. The triazolyalanine 12 was proposed ĂƐĂŵŝŵŝĐŽĨʋ-pHis by Kee et 
al., but not used in antibody generation.102 
 
 
 
Figure 8 Triazolyl containing peptides 16 and 17 used to generate pHis antibodies.74 
 
Monoclonal antibodies raised with peptides 16 recognised peptides containing residue 16 
but not residue 17 on dot blots and vice versa for 17. The monoclonal antibodies were used 
in Western blots of many mammalian whole cell lysates and in pHis protein enrichment.74 
Hunter et al. found significant overlap of ʋ-and ʏ-pHis proteins binding to all monoclonals in 
the enrichment data.  It is important to point out that in the initial report by Kee et al. the 
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use of Histone H4 peptide 11 gave peptide sequence dependent polyclonal antibodies and 
their later method using triazole ethylamine 15 gave cross-reactive polyclonal antibodies for 
pHis and pTyr.76, 102  
ǀĂůƵĂƚŝŽŶ ŽĨ ƉŽƚĞŶƚŝĂů ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ Ɖ,ŝƐ ĂŶĚ ƉdǇƌ ďŝŶĚŝŶŐ ĚŽŵĂŝŶƐ ŝŶĚŝĐĂƚĞĚ ƚŚĂƚ
ƉĞƉƚŝĚĞƐĐŽŶƚĂŝŶŝŶŐƵŶƉƌŽƚĞĐƚĞĚƚƌŝĂǌŽůĞƌĞƐŝĚƵĞϭϲ ?ĂƐƌĞƉůĂĐĞŵĞŶƚĨŽƌƉdǇƌ ?ĂƌĞĐĂƉĂďůĞŽĨ
ƐƚƌŽŶŐůǇďŝŶĚŝŶŐƚŽƚŚĞƉƌŽƚŽƚǇƉŝĐĂůƉdǇƌďŝŶĚŝŶŐGrb2^, ?ĚŽŵĂŝŶƐ ? ? ? ?,ŽǁĞǀĞƌ ?ƚŚŝƐƌĞƐƵůƚ
ĂƉƉĂƌĞŶƚůǇ ĐŽŶƚƌĂĚŝĐƚĞĚĂ ƉƌĞǀŝŽƵƐ ƐƚƵĚǇ ƚŚĂƚ ƐŚŽǁĞĚ ƚŚĂƚ ʏ-Ɖ,ŝƐ ĐŽƵůĚŶŽƚ ƐƵďƐƚŝƚƵƚĞ ĨŽƌ
ƉdǇƌ ŝŶ ŚŝŐŚ-ĂĨĨŝŶŝƚǇ ďŝŶĚŝŶŐ of ƉĞƉƚŝĚĞƐ ƚŽ ƉdǇƌ ďŝŶĚŝŶŐ Grb2 ^, ? ĚŽŵĂŝŶƐ.110 It is worth 
noting that peptides containing a pHis substitution were not considered in the experimental 
setup by McAllister et al. As such, it is possible that the Grb2 SH2 binding observed most 
likely resulted from the ability of triazole residue 16 to mimic both pTyr and pHis. Thus, their 
results are in line with data from antibody generation using the triazole ethylamine 15 (vide 
supra) and supports the notion that this triazole residue has a hybrid functionality for both 
pHis and pTyr.76 Furthermore, the peptide sequence dependant antibodies generated to  
Histone H4 peptide 9 cross-reacted with pTyr substitution (Rb.#3 antibodies showed 
significant cross reactivity with pTyr, see Figure S4, supplementary information).102 This 
indicates that peptides containing this triazole residue may not be entirely suitable as tools 
to raise pHis peptide sequence dependant antibodies. 
 
 
Due to the limitations of the triazole residue 17 Kee et al., reported a second generation 
pyrazole ethylamine 17 as a ʏ-pHis analogue (Figure 9).103 DFT calculations by Kee et al., 
show that the pyrazole analogue 18 residue not only closely matches the ʏ-pHis residue in 
structure but also electronically.103 Affinity purified polyclonal antibodies raised to pyrazole 
analogue 18 conjugated to KLH via a linker were found to strongly detect pHis over pTyr, as 
assessed by ELISA against His phophorylated BSA and phosphorylated amino acid 
conjugates. Concurrently, Lilley et al. reported antibodies raised with the pyrazole amino 
acid 19 conjugated to KLH via a linker (Figure 9).111 These polyclonal antibodies were also 
found to have strong selectivity for pHis over pTyr, on dot blots, immunoblots and ELISA 
against BSA phosphorylated amino acid conjugates as standards. Polyclonal antibodies 
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reported by Kee et al., were used to detect various in vitro His phosphorylated proteins 
including PGAM1, mammalian histone H4 and PtsI, whilst those by Lilley et al. antibodies 
were used to detect immunoprecipitated protein 'ɴĂŶĚďŽƚŚEW<-A/B  from HBE cells.103, 
111 
 
 
 
 
 
 
Figure 9 ʏ-pHis pyrazole analogues 18 and 19. 
 
Amino acid substitutions as a phosphomimetic 
A useful genetic approach to mimic constitutive phosphorylation of the hydroxy amino acids 
often involves mutation or substitution of Ser/Thr with Glu or Asp to mimic pSer/pThr or 
constitutive phosphorylation of these residues. Conversely, substituting Ser or Thr with 
alanine (Ala) prevents potential phosphorylation and mimics constitutive 
dephosphorylation. However, Ala is not a perfect mimic for Ser, due to the absence of the 
hydroxy group. The properties of the phosphoryl and carboxy groups (number of oxygen 
atoms available for bonding, geometry, size and pKa) differ and these substitutions do not 
work successfully in every case, highlighting the differences in the structure of the epitope 
in these substitutions. Interestingly, pSer/pThr antibodies do not recognize substituted Asp 
or glutamate (Gln). There is no natural mimic for pTyr. Gln is occasionally reported as a pTyr 
mimic, but it bears very little chemical similarity to pTyr.  
Similarly, there are no natural mimics for His or pHis but several reports exist in the 
literature involving Ala, phenylalanine (Phe), leucine (Leu) and asparagine (Asn) (possessing 
hydrophobic, aromatic or polar neutral side chains) substitution of His (a charged side 
chain).18, 112, 113   
Several unnatural pTyr analogues have been developed and incorporated into synthetic 
peptides by SPPS and, in some cases, this was followed by ligation of the synthetic peptide 
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to recombinant proteins of interest. The pTyr analogues, phosphonomethylphenylalanine 
(Pmp), and difluorophosphono-methylphenylalanine (F2Pmp), have been invaluable tools in 
understanding the role of pTyr in cellular processes. Peptides containing pTyr analogues p-
carboxymethylphenylalanine have also been used as haptens for generation of selective 
phospho-ĂŶƚŝďŽĚŝĞƐ ?ƉŚŽƐƉŚĂƚĂƐĞŝŶŚŝďŝƚŽƌƐ ?ĂĸŶŝƚǇůŝŐĂŶĚƐĂŶĚŝŶƐƚƌƵĐƚƵƌĂůƐƚƵĚŝĞƐ ?114 
ĚǀĂŶĐĞƐ ŝŶ ŐĞŶĞƚŝĐ ĐŽĚĞ ĞǆƉĂŶƐŝŽŶ ďĞǇŽŶĚ ƚŚĞ ŶĂƚƵƌĂůůǇ ĞŶĐŽĚĞĚ ĂŵŝŶŽ ĂĐŝĚƐ ŚĂǀĞ ĂůƐŽ
ĞŶĂďůĞĚƐŝƚĞ-ƐƉĞĐŝĨŝĐŝŶĐŽƌƉŽƌĂƚŝŽŶŽĨƉdǇƌĂŶĂůŽŐƵĞƐĂŶĚŽƚŚĞƌƵŶŶĂƚƵƌĂůĂŵŝŶŽĂĐŝĚƐ ?h ?
ŝŶƚŽƉƌŽƚĞŝŶƐƚŽŐĞŶĞƌĂƚĞƉƌŽƚĞŝŶƐǁŝƚŚĞŶŚĂŶĐĞĚƉƌŽƉĞƌƚŝĞƐĂŶĚƉƌŽďĞƐĨŽƌĨƵŶĐƚŝŽŶ ? ? ? ? ?  ? ? ?
/ŶŽƌĚĞƌƚŽŝŶĐŽƌƉŽƌĂƚĞƚŚĞhĂƚĂŐĞŶĞƚŝĐĂůůǇĚĞĨŝŶĞĚƉŽƐŝƚŝŽŶŝŶĂƉŽůǇƉĞƉƚŝĚĞĐŚĂŝŶ ?ƚŚĞ
hŽŶĐĞĂĚĚĞĚƚŽĐĞůůƐ ŝƐƌĞĐŽŐŶŝƐĞĚďǇĂŶŽƌƚŚŽŐŽŶĂůƐǇŶƚŚĞƚĂƐĞ ?ƚZEƉĂŝƌĂŶĚƵƐĞĚƚŽ
ĂŵŝŶŽĂĐǇůĂƚĞƚŚĞŽƌƚŚŽŐŽŶĂůƚZEǁŚŝĐŚŝƐƚŚĞŶĚĞĐŽĚĞĚďǇƚŚĞƌŝďŽƐŽŵĞŝŶƌĞƐƉŽŶƐĞƚŽĂ
ďůĂŶŬĐŽĚŽŶ ?ŝŶƐĞƌƚĞĚŝŶƚŽƚŚĞŐĞŶĞŽĨŝŶƚĞƌĞƐƚďǇƐŝƚĞ-ĚŝƌĞĐƚĞĚŵƵƚĂŐĞŶĞƐŝƐĂƚĂƉŽƐŝƚŝŽŶŽĨ
ŝŶƚĞƌĞƐƚ ?ŽŶƚŚĞŵZE ?dŚƵƐĨŽƌŝŶĐŽƌƉŽƌĂƚŝŽŶŽĨƉ,ŝƐĂŶĂůŽŐƵĞ ?ƚŚŝƐĂƉƉƌŽĂĐŚǁŽƵůĚƌĞƋƵŝƌĞ
ĚĞǀĞůŽƉŵĞŶƚ ŽĨ ĂͿ ĂŶ ĂŵŝŶŽĂĐǇů-ƚƌĂŶƐĨĞƌ ZE  ?ƚZE ? ƐǇŶƚŚĞƚĂƐĞ ?ƚZE ƉĂŝƌ ƚŚĂƚ ŝƐ
ŽƌƚŚŽŐŽŶĂůƚŽĞŶĚŽŐĞŶŽƵƐƐǇŶƚŚĞƚĂƐĞƐĂŶĚƚZEƐŝŶƚŚĞŚŽƐƚĐĞůůƐ ?ďͿŵĞƚŚŽĚƐƚŽĂĚĂƉƚŽƌ
ĐŽŶǀĞƌƚƚŚĞĂŵŝŶŽĂĐǇů-ƚZEƐǇŶƚŚĞƚĂƐĞĂŵŝŶŽĂĐŝĚƐƉĞĐŝĨŝĐŝƚǇƐŽƚŚĂƚ ŝƚƵŶŝƋƵĞůǇƵƐĞƐŽŶůǇ
ƚŚĞ Ɖ,ŝƐ ĂŶĂůŽŐƵĞ ĂŶĚŶŽ ŶĂƚƵƌĂů ĂŵŝŶŽ ĂĐŝĚƐ ?ĐͿ Ă ďůĂŶŬ ĐŽĚŽŶ ƚŽ ĚŝƌĞĐƚ ŝŶƐĞƌƚŝŽŶ ŽĨ ƚŚĞ
Ɖ,ŝƐ ĂŶĂůŽŐƵĞ ?ĚͿ ŵŽĚŝĨŝĐĂƚŝŽŶ ŽĨ h  ?Ɖ,ŝƐ ĂŶĂůŽŐƵĞ ? ĐŚĂƌŐĞ ƚŽ ĂůůŽǁ ŝŶĐƌĞĂƐĞĚ ĐĞůůƵůĂƌ
ƉĞƌŵĞĂďŝůŝƚǇ ? ĂŶĚĞͿ ƐƵďƐĞƋƵĞŶƚůǇ ? Ă ĐŚĞŵŽ-ƐĞůĞĐƚŝǀĞ ĐŚĞŵŝĐĂů ŵŽĚŝĨŝĐĂƚŝŽŶ ƌĞĂĐƚŝŶŐ ŽŶůǇ
ǁŝƚŚƚŚĞŝŶĐŽƌƉŽƌĂƚĞĚƉ,ŝƐĂŶĂůŽŐƵĞďƵƚŶŽƚƚŚĞŶĂƚƵƌĂůĂŵŝŶŽĂĐŝĚƐŽŶƚŚĞƉƌŽƚĞŝŶƵƚŝůŝƐĞĚ
ƚŽ ŵŽĚŝĨǇ ƚŚĞ h ?  ŵŽŶŐ ƐĞǀĞƌĂů ŽƚŚĞƌ ƉŽƐƐŝďŝůŝƚŝĞƐ ĂŶĚ ĂĚǀĂŶƚĂŐĞƐ ? ĞǆƉƌĞƐƐŝŽŶ ŽĨ
ƉƌŽƚĞŝŶƐ ŝŶ ǁŚŝĐŚ Ɖ,ŝƐ ŝƐ ƐƵďƐƚŝƚƵƚĞĚ ǁŝƚŚ Ă ƐƚĂďůĞ Ɖ,ŝƐ ĂŶĂůŽŐƵĞ ǁŝůů ŶŽƚ ŽŶůǇ ŚĞůƉ ŝŶ
ƐƚƌƵĐƚƵƌĂů ?ĨƵŶĐƚŝŽŶĂůƐƚƵĚŝĞƐďƵƚǁŝůůŽǀĞƌĐŽŵĞƚŚĞĐŽŵƉůĞǆŝƚŝĞƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚŝĚĞŶƚŝĨǇŝŶŐ
ƚŚĞĐŽŐŶĂƚĞŬŝŶĂƐĞƐĂŶĚƉŚŽƐƉŚĂƚĂƐĞƐƉƌŝŽƌƚŽƐƚƵĚǇŝŶŐƚŚĞƌŽůĞŽĨƉ,ŝƐƉŚŽƐƉŚŽƌǇůĂƚŝŽŶĂƚ
ƐƉĞĐŝĨŝĐ ƐŝƚĞƐ ?  ZĞĐĞŶƚůǇ ? Ă ŵĞƚŚŽĚ ŚĂƐ ďĞĞŶ ĚĞǀĞůŽƉĞĚ ƚŽ ƉƌŽĚƵĐĞ ƉƵƌĞ ƚǇƌŽƐŝŶĞ-
ƉŚŽƐƉŚŽƌǇůĂƚĞĚ ƉƌŽƚĞŝŶƐ ďǇ ŐĞŶĞƚŝĐ ĞŶĐŽĚŝŶŐ ŽĨ Ă ƐƚĂďůĞ ĂŶĚ ŶĞƵƚƌĂů ƉŚŽƐƉŚŽƚǇƌŽƐŝŶĞ
ĂŶĂůŽŐƵĞ ĨŽůůŽǁĞĚ ďǇ ƐƵďƐĞƋƵĞŶƚ ĚĞƉƌŽƚĞĐƚŝŽŶ ? ? ? ? dŚŝƐ ĂƉƉƌŽĂĐŚ ƌĞƐƵůƚĞĚ ŝŶ ƐŝƚĞ-ƐƉĞĐŝĨŝĐ
ŝŶĐŽƌƉŽƌĂƚŝŽŶ ŽĨ ŶĂƚŝǀĞ ƉŚŽƐƉŚŽƚǇƌŽƐŝŶĞ ŝŶƚŽ ƐĞǀĞƌĂů ĚŝĨĨĞƌĞŶƚ ƉƌŽƚĞŝŶƐ ŝŶĐůƵĚŝŶŐ ƵďŝƋƵŝƚŝŶ
ĂŶĚ ƌĞǀĞĂůĞĚ Ă ƉŽƚĞŶƚŝĂů ŶĞŐĂƚŝǀĞ ƌĞŐƵůĂƚŽƌǇ ƌŽůĞ ŽĨ ƵďŝƋƵŝƚŝŶ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ Ăƚ dǇƌ ? ? ?
ǁŚŝĐŚ ĞǆĐůƵƐŝǀĞůǇ ŽĐĐƵƌƐ ŝŶ ĐĂŶĐĞƌŽƵƐ ƚŝƐƐƵĞ ďƵƚ ǁŚŽƐĞ ƐŝŐŶŝĨŝĐĂŶĐĞ ŚĂƐ ŚŝƚŚĞƌƚŽ ďĞĞŶ
ƵŶŬŶŽǁŶ ? 
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Conclusion  
The importance of pHis in mammalian systems continues to be uncovered and suggests pHis 
function may prove to be much more extensive than presently understood. The data 
suggest conversion of one isomer of pHis to the other occurs via a bimolecular process 
under certain conditions but there is no data to support pHis isomerisation via a 
unimolecular process. Therefore, a specific pHis isomer within a protein (which can be 
thought of as an isolated system) is unlikely to undergo facile conversion to the isomeric 
pHis. However, caution must be used when handling pHis and pHis proteins due to the 
labile/ transferable nature of the pHis phosphoryl group under certain conditions. 
The half-life of pHis residues in proteins is an important question to be addressed. It is likely 
that the half-life will depend on the pHis isomer, solutes in solution and protein structure. A 
hypothetical example could be an exposed pHis residue in the presence of calcium ions 
where changes in calcium ion concentrations regulate pHis hydrolysis. The presence of pHis 
residues which have long life-times could imply a need for regulatory phosphatases, whilst 
residues with relatively short life times may be self-regulating. 
It is likely that mass spectrometry (MS) will be used increasingly to detect pHis and the 
TRIPLET fingerprint approach described by Kee et al. will help in pHis peptide analysis. For 
many other post-translation modifications if enough is known about the proteins and a pure 
sample can be obtained, MS analysis alone may suffice. However, due to the acid labile 
nature of pHis and the presence of two isomers other methods of detection in parallel are 
needed. Methods such as phosphoamino acid analysis and 31P NMR allow pHis isomers to be 
distinguished, but require standards. 
With the emergence of the long awaited pHis analogues and antibodies, advances are 
anticipated in the detection and enrichment of existing/unknown pHis proteins and in the 
understanding of the cellular function of pHis 
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